[1]
|
S. H. Swerdlow, E. Campo, N. L. Harris, et al., “WHO Classifiction of Tumours of Haematopoietic and Lymphoid Tissues,” IARC Press, Lyon, 2008.
|
[2]
|
S. Rollinson, P. Roddam, E. Kane, E. Roman, R. Cartwright, A. Jack and G. J. Morgan, “Polymorphic Variation within the Glutathione S-Transferase Genes and Risk of Adult Acute Leukemia,” Carcinogenesis, Vol. 21, No. 1, 2000, pp. 43-47. doi:10.1093/carcin/21.1.43
|
[3]
|
S. S. Franco, A. C. Nardocci and W. M. Günther, “PAH Biomarkers for Human Health Risk Assessment: A Review of the State-of-the-Art,” Cadernos de Saúde Pública, Vol. 24, Supplement 4, 2008, pp. s569-s580.
|
[4]
|
I. Cascorbi, J. Brockm?ller and I. Roots, “A C4887A Polymorphism in Exon 7 of Human CYP1A1: Population Frequency, Mutation Linkages, and Impact No Lung Cancer Suscepbtility,” Cancer Research, Vol. 56, No. 21, 1996, pp. 4965-4969.
|
[5]
|
Y. Li, R. C. Millikan, D. A. Bell, L. Cui, C. K. T. Tse, B. Newman and K. Conway, “Cigarette Smoking, Cytochrome P4501 Polymorphisms, and Breast Cancer among African-American and White Women,” Breast Cancer Research, Vol. 6, No. 4, 2004, pp. R460-R473.
doi:10.1186/bcr814
|
[6]
|
R. Montero, A. Araujo, P. Carranza, V. Mejía-Loza, L. Serrano, A. Albores, J. E. Salinas and R. Camacho-Carranza, “Genotype Frequencies of Polymorphic GSTM1, GSTT1, and Cytochrome P450 CYP1A1 in Mexicans,” Vol. 79, No. 3, 2007, pp. 299-312.
|
[7]
|
M. T. Voso, F. D’Alo, R. Putzulu, L. Mele, A. Scardocci, P. Chiusolo, et al., “Negative Prognostic Value of Glutathione S-Transferase (GSTM1 and GSTT1) Deletions in Adult Acute Myeloid Leukemia,” Blood, Vol. 100, No. 8, 2002, pp. 2703-2707. doi:10.1182/blood.V100.8.2703
|
[8]
|
P. Bolufer, M. Collado, E. Barragan, M. J. Calasanz, D. Colomer, M. Tormo, M. González, S. Brunet, M. Batlle, J. Cervera and M. A. Sanz, “Profile of Polymorphisms of Drug-Metabolising Enzymes and the Risk of TherapyRelated Leukaemia,” British Journal of Haematology, Vol. 36, No. 4, 2007, pp. 590-596.
doi:10.1111/j.1365-2141.2006.06469.x
|
[9]
|
L. A. F. Pelloso, I. D. C. G. Silva, N. C. R. Souza, C. A. A. Botelho, M. Yamamoto and M. L. L. F. Chauffaille, “CYP1A1 Polymorphisms Modify Overall Survival in Acute Myeloid Leukemia Patients,” Leukemia and Lymphoma, Vol. 48, No. 6, 2007, pp. 1211-1215.
doi:10.1080/10428190701332431
|
[10]
|
A. P. Singh, P. P. Shah, M. Ruwali, N. Mathur, M. C. Pant and D. Parmar, “Polymorphism in Cytochrome P4501A1 is Significantly Associated with Head and Neck Cancer Risk,” Cancer Investigation, Vol. 27, No. 8, 2009, pp. 869-876. doi:10.1080/07357900902849657
|
[11]
|
C. M. Wright, J. E. Larsen, M. L. Colosimo, J. J. Barr, L. Chen, R. E. McLachlan, I. A. Yang, R. V. Bowman and K. M. Fong, “Genetic Association Study of CYP1A1 Polymorphisms Identifies Risk Haplotypes in Nonsmall Cell Lung Cancer,” European Respiratory Journal, Vol. 35, No. 1, 2010, pp. 152-159.
doi:10.1080/07357900902849657
|
[12]
|
M. L. L. F. Chauffaille, M. S. Figueiredo, R. Beltrani, et al., “Acute Promyelocytic Leukemia: The Study of t(15;17) Translocation by Fluorescent in Situ Hybridization, Reverse Transcriptase-Polymearse Chain Reaction and Cytogentic Techniques,” Brazilian Journal of Medical and Biological Research, Vol. 34, No. 6, 2001, pp. 735-743. doi:10.1590/S0100-879X2001000600006
|
[13]
|
D. Grimwade, H. Walker, G. Harrison, F. Oliver, S. Chatters, et al., “The Predicitive Value of Hierarchial Cytogenetic Classification in Older Patients with Acute Myeloid Leukemia (AML): Analysis of 1065 Patients Entered into the United Kingdom Medical Research Council AML11 Trial,” Blood, Vol. 98, No. 5, 2001, pp. 1312-1320.
doi:10.1182/blood.V98.5.1312
|
[14]
|
G. J. F. Gattás and J. A. Soares-Vieira, “Cytochrome P450-2E1 and Glutathione S-Transferase um Polymorphims among Caucasians and Mulattoes from Brazil,” Occupational Medicine, Vol. 50, No. 7, 2000, pp. 508-511. doi:10.1093/occmed/50.7.508
|
[15]
|
G. J. F. Gattás, M. Kato, J. A. Soares-Vieira, M. S. Siraque, P. Kohler, L. Gomes, M. A. V. Rego and S. P. Bydlowski, “Ethnicity and Glutathione S-Transferase (GSTM1/ GSTT1) Polymorphisms in a Brazilian Population,” Brazilian Journal of Medical and Biological Research, Vol. 37, No. 4, 2004, pp. 451-458.
doi:10.1093/occmed/50.7.508
|
[16]
|
F. D’Alò, M. T. Voso, F. Guidi, G. Massini, A. Scardocci, S. Sica, L. Pagano, S. Hohaus and G. Leone, “Polymorphisms of CYP1A1 and Glutathione S-Transferase and Susceptbility to Adult Acute Myeloid Leukemia,” Haematologica, Vol. 89, No. 6, 2004, pp. 664-670.
|
[17]
|
V. R. Arruda, C. S. P. Lima, C. R. E. Grignoli, M. B. Melo, I. Lorand-Metze, F. L. Alberto, S. T. O. Saad and F. F. Costa, “Increased Risk for Acute Myeloid Leukaemia in Individulas with Glutathione S-Transferase mu 1 (GSTM1) and Theta 1 (GSTT10) gene Defects,” European Journal of Haematology, Vol. 66, No. 6, 2001, pp. 383-388. doi:10.1093/occmed/50.7.508
|
[18]
|
T. Basu, R. E. Gale, C. Fidler, P. E. Peto, J. Boutwood and J. S. Wainscoat, “Glutahione S-Transferase Theta 1 (GSTT1) Gene Defect in Myelodysplasia and Acute Myeloid Leukemia,” Lancet, Vol. 349, No. 9063, 1997, p. 1450. doi:10.1093/occmed/50.7.508
|
[19]
|
M. H. Woo, J. J. Shuster and C. Chen, “Glutathione S-Transferase Genotypes in Children Who Developed Treatment Related Acute Myeloid Malignancies,” Leukemia, Vol. 14, No. 2, 2000, pp. 232-237.
doi:10.1038/sj.leu.2401660
|
[20]
|
L. A. Pelloso, M. L. Chauffaille, F. S. Ghaname, M. Yamamoto, D. M. Bahia, J. Kerbauy, “Karyotype in Acute Myeloid Leukemia: Importance and Type of Aberrations in 30 Patients at Diagnosis,” Revista da Associa??o Médica Brasileira, Vol. 49, No. 2, 2003, pp. 150-155.
doi:10.1590/S0104-42302003000200032
|
[21]
|
C. A. Rodrigues, M. L. Chauffaille, L. A. Pelloso, F. S. Ghaname, D. M. Kerbauy, M. G. Campos and M. Yamamoto, “Acute Myeloid Leukemia in Elderly Patients: Experience of a Single Center,” Brazilian Journal Of Medical and Biological Research, Vol. 36, No. 6, 2003, pp. 703-708. doi:10.1590/S0100-879X2003000600004
|
[22]
|
M. L. Slovak, K. J. Kopecky, D. Cassileth, D. H. Harrington, K. S. Thiel, A. Mohamed, et al., “Karyotypic Analysis Predicts Outcome of Preremission and Postremission Therapy in Adult Acute Myeloid Leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study,” Blood, Vol. 96, No. 13, 2000, pp. 4075-4083.
|